Annual Report 2005 - Boehringer Ingelheim
Annual Report 2005 - Boehringer Ingelheim
Annual Report 2005 - Boehringer Ingelheim
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
4 Notes to the consolidated profit and loss statement<br />
The consolidated profit and loss statement is presented in line with the total cost method.<br />
4.1 Net sales<br />
by business and business segment (in millions of EUR) <strong>2005</strong> 2004<br />
Human Pharmaceuticals 9,174 7,822<br />
of which: Prescription Medicines 7,247 6,183<br />
Consumer Health Care 1,052 970<br />
Industrial Customer 847 654<br />
Other sales 28 15<br />
Animal Health 361 335<br />
9,535 8,157<br />
by geographic region (in millions of EUR) <strong>2005</strong> 2004<br />
Europe 3,117 2,622<br />
of which: Germany 816 656<br />
Americas 4,559 3,905<br />
of which: USA/Canada/Mexico 4,219 3,625<br />
Asia, Australasia, Africa 1,859 1,630<br />
of which: Japan 1,232 1,142<br />
4.2 Material costs<br />
9,535 8,157<br />
(in millions of EUR) <strong>2005</strong> 2004<br />
Costs of raw material, supplies and goods for resale 1,351 1,076<br />
Expenditure on services 262 213<br />
4.3 Personnel costs<br />
1,613 1,289<br />
(in millions of EUR) <strong>2005</strong> 2004<br />
Salaries and wages 2,087 1,913<br />
Social benefits and retirement benefits 584 530<br />
of which: retirement benefits 155 154<br />
2,671 2,443<br />
The interest component with respect to the increase in pensions and similar obligations is included in<br />
financial income rather than in personnel costs and is, therefore, not included in the operating result<br />
of the company.<br />
Consolidated Financial Statements <strong>2005</strong> 107
Change language